Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
DierenDokters has been acquired by VetPartners
DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.Learn more
Connexicon Medical has been acquired by Advanced Medical Solutions PLC
Connexicon Medical Ltd has been sold to Advanced Medical Solutions PLC.Learn more
Therapy Equipment has been acquired by ESAB Corporation
Owner Venture Managers has sold Therapy Equipment Ltd. to ESAB Corporation.Learn more